The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In Acromegaly
Trial Parameters
Brief Summary
This is an observational, retrospective, national multicenter study aimed to evaluate the impact and efficacy of Time To Switch (TTS) from first-line to second-line medical therapy in Acromegaly.
Eligibility Criteria
Inclusion Criteria: * Adult men and women (age ≥ 18 years) affected by acromegaly, including those of childbearing age * Patients inadequately controlled with first generation somatostatin analogues (GH ≥1 μg/L and IGF-1 \>1.3×ULN) * Second line medical treatment (Pasireotide; Pegvisomant only; combination Pegvisomant + 1st generation SSA) after use of first-line medical treatment * At least 12 months of follow up during 2nd line therapy * Signature of the informed consent to the study Exclusion Criteria: * age ≤18 years * Pregnant and/or breastfeeding women * Patients unable to understand and sign the Informed Consent